CV9103

BIOLOGICAL2 trials

Sponsors

CureVac, University of Florida

Conditions

Hormonal Refractory Prostate CancerHormone Refractory Prostate Cancer

Phase 1

Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease

CompletedNCT00831467

CureVacHormonal Refractory Prostate Cancer

Start: 2009-01-31End: 2013-09-30Updated: 2018-03-20

RNActive®-Derived Therapeutic Vaccine

TerminatedNCT00906243

University of FloridaHormone Refractory Prostate Cancer

Start: 2009-05-31End: 2010-12-31Updated: 2012-04-04